PT  - JOURNAL ARTICLE
AU  - Rossi, P. Giorgi
AU  - Ferroni, E.
AU  - Alegiani, S. Spila
AU  - Pitter, G.
AU  - Leoni, O.
AU  - Cereda, D.
AU  - Marino, M.
AU  - Pellizzari, M.
AU  - Sultana, J.
AU  - Trifirò, G.
AU  - Massari, M.
AU  - ,
TI  - Survival of hospitalized COVID-19 patients in Northern Italy: a population-based cohort study by the ITA-COVID19 Network
AID  - 10.1101/2020.05.15.20103119
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.15.20103119
4099  - http://medrxiv.org/content/early/2020/06/09/2020.05.15.20103119.short
4100  - http://medrxiv.org/content/early/2020/06/09/2020.05.15.20103119.full
AB  - Background COVID-19 case fatality rate in hospitalized patients varies across countries and studies, but reliable estimates specific for age, sex, and comorbidities are needed to design trials for COVID-19 interventions. Aim of this study is to provide population-based survival curves of hospitalized COVID-19 patients.Methods A cohort study was conducted in Lombardy, Veneto, and Reggio Emilia using COVID-19 registries linked to hospital discharge databases containing patient clinical histories. All patients with positive SARS-CoV-2 RT-PCR test on oral/nasopharyngeal swabs hospitalized from 21st February to 21st April 2020 were identified. Kaplan Meier survival estimates were calculated at 14 and 30 days for death in any setting, stratifying by age, sex and Charlson Index.Findings Overall, 42,926 hospitalized COVID-19 patients were identified. Patients’ median age was 69 years (IQR: 57-79), 62·6% were males, 69·4% had a Charlson Index of 0. In total, 11,205 (26·1%) patients died over a median follow-up of 24 days (IQR: 10-35). Survival curves showed that 22·0% of patients died within 14 days and 27·6% within 30 days of hospitalization. Survival was higher in younger patients and in females. Younger patients with comorbidities had a lower survival than older ones with comorbidities.Interpretation Over 27% of hospitalized COVID-19 patients died within one month in three areas of Northern Italy that were heavily affected by SARS-CoV-2 infection. Such a high fatality rate suggests that trials should focus on survival and have follow-up of at least one month.Funding The study did not receive any external funding.Research in context Evidence before this studyTwo recent systematic reviews with meta-analyses report case fatality rates of three to four percent in COVID-19 patients. Most studies on hospitalized cohorts report only slightly higher figures. These figures do not correspond to those derived from routinely collected clinical data in most European countries, reporting a 10% case fatality rate which has been increasing over time since the epidemic started.Robust and precise survival estimates of hospitalized COVID-19 patients which take into account prognostic factors such as age, sex and burden of comorbidities are needed to design appropriate phase II and phase III clinical studies of drugs targeting COVID-19.Added value of this study In this study we present the first survival estimates by age, sex and Charlson index for a large population-based cohort of Italian hospitalized COVID-19 patients.Implications of all the available evidence Over 27% of COVID-19 patients died within one month from hospital admission. Such a high fatality rate suggests that studies should prioritize mortality as primary outcome. Furthermore, we found that the fatality rate reaches a plateau 30 days after hospitalization, suggesting that studies should have at least one month of follow up to observe deaths; shorter follow-up could lead to overestimation of treatment benefits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Ethics Committee of the Italian National Institute of Health on 18th March 2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be updated periodically. Aggregate data are available upon submission of a request which describes the research objectives and a protocol for analyses to the local competent authorities: for Lombardy, queries should be submitted to a specific COVID-19 Committee, identified by the Directorate General for Health (under DDG n. 3019/2020), e-mail accessodatic19@regione.lombardia.it; for Veneto to the Health Direction of the Azienda Zero, e-mail: direzione.sanitaria@azero.veneto.it; for Reggio Emilia to the Comitato Etico Area Vasta Emilia Nord, Reggio Emilia office, e-mail: mariafrancesca.paolo@ausl.re.it. Data will be available at least for seven years from the approval of the study.